Restricted accessResearch articleFirst published online 2015-1
Preliminary Findings of Long-Term Neurodevelopmental Outcomes of Infants Treated With Intravenous Fat Emulsion Reduction for the Management of Parenteral Nutrition–Associated Cholestasis
Introduction: Parenteral nutrition–associated cholestasis (PNAC) is linked with the administration of soybean-based intravenous fat emulsion (IVFE). IVFE reduction (IFER) may be an effective management strategy for PNAC; however, long-term associated neurodevelopmental outcomes (NDOs) for infants undergoing IFER have not been measured previously. This single-institution, prospective study examined the risk for negative NDOs and key predictors of NDOs associated with IFER. Methods: Patients (2–5 years) treated with soybean-based IFER as neonates underwent NDO measurements, including Ages and Stages Questionnaires–3 (ASQ-3), Parents’ Evaluations of Developmental Status (PEDS), and Behavior Assessment System for Children, Second Edition Preschool, Parent (BASC-2 PRS-P). The relationship between NDOs and predictive variables was evaluated. Results: A total of 25 children had a complete PEDS survey, and 17 were found to be “not at risk.” The BASC-2 PRS-P evaluation (n = 18 patients) showed that all 4 composite domains fell within the normative developmental range, and 67%–89% of patients were observed to be “typically developing.” For the primary outcome measure, ASQ-3, 82.4%–94.4% of patients were “not at risk.” Logistical regression analyses were performed to examine risk factors contributing to negative NDOs. Of children completing all NDO studies, IFER-related variables (eg, development of essential fatty acid deficiency, duration of IFER, and mean IVFE dose) were not found to be predictors of adverse NDOs. Conclusions: This study represents the first report of NDOs in pediatric patients treated with IFER. IFER-treated patients score within the normative range most of the time. IFER-related variables were not found to be associated with negative NDOs. The results set the stage for a larger, multicenter, prospective study.
KellyDA. Liver complications of pediatric parenteral nutrition—epidemiology. Nutrition. 1998;14:153-157.
2.
KellyDA. Intestinal failure-associated liver disease: what do we know today?Gastroenterology. 2006;130:S70-S77.
3.
CarterBAKarpenSJ. Intestinal failure-associated liver disease: management and treatment strategies past, present, and future. Semin Liver Dis. 2007;27:251-258.
4.
Ginn-PeaseMEPantalosDKingDR. TPN-associated hyperbilirubinemia: a common problem in newborn surgical patients. J Pediatr Surg. 1985;20:436-439.
5.
SpencerAUNeagaAWestB. Pediatric short bowel syndrome: redefining predictors of success. Ann Surg. 2005;242:403-412.
6.
KoseesirikulPChotinaruemolSUkarapolN. Incidence and risk factors of parenteral nutrition–associated liver disease in newborn infants. Pediatr Int. 2012;54:434-436.
7.
DrongowskiRACoranAG. An analysis of factors contributing to the development of total parenteral nutrition-induced cholestasis. JPEN J Parenter Enteral Nutr. 1989;13:586-589.
8.
CarterBAShulmanRJ. Mechanisms of disease: update on the molecular etiology and fundamentals of parenteral nutrition associated cholestasis. Nat Clin Pract Gastroenterol Hepatol. 2007;4:277-287.
9.
MossRLAmiiLA. New approaches to understanding the etiology and treatment of total parenteral nutrition–associated cholestasis. Semin Pediatr Surg. 1999;8:140-147.
10.
KumpfVJ. Parenteral nutrition–associated liver disease in adult and pediatric patients. Nutr Clin Pract. 2006;21:279-290.
11.
RangelSJCalkinsCMCowlesRA. Parenteral nutrition–associated cholestasis: an American Pediatric Surgical Association Outcomes and Clinical Trials Committee systematic review. J Pediatr Surg. 2012;47:225-240.
12.
DiamondIRSterescuAPencharzPBKimJHWalesPW. Changing the paradigm: Omegaven for the treatment of liver failure in pediatric short bowel syndrome. J Pediatr Gastroenterol Nutr. 2009;48:209-215.
13.
GuraKMLeeSValimC. Safety and efficacy of a fish-oil–based fat emulsion in the treatment of parenteral nutrition–associated liver disease. Pediatrics. 2008;121:e678-e686.
14.
AllardyceDB. Cholestasis caused by lipid emulsions. Surg Gynecol Obstet. 1982;154:641-647.
15.
ColombVJobert-GiraudALacailleFGouletOFournetJCRicourC. Role of lipid emulsions in cholestasis associated with long-term parenteral nutrition in children. JPEN J Parenter Enteral Nutr. 2000;24:345-350.
16.
CoberMPKilluGBrattainAWelchKBKunisakiSMTeitelbaumDH. Intravenous fat emulsions reduction for patients with parenteral nutrition-associated liver disease. J Pediatr. 2012;160:421-427.
17.
CoberMPTeitelbaumDH. Prevention of parenteral nutrition-associated liver disease: lipid minimization. Curr Opin Organ Transplant. 2010;15:330-333.
18.
NehraDFallonEMCarlsonSJ. Provision of a soy-based intravenous lipid emulsion at 1 g/kg/d does not prevent cholestasis in neonates. JPEN J Parenter Enteral Nutr. 2013;37:498-505.
19.
SanchezSEBraunLPMercerLDSherrillMStevensJJavidPJ. The effect of lipid restriction on the prevention of parenteral nutrition–associated cholestasis in surgical infants. J Pediatr Surg. 2013;48:573-578.
20.
RollinsMDWardRMJacksonWD. Effect of decreased parenteral soybean lipid emulsion on hepatic function in infants at risk for parenteral nutrition-associated liver disease: a pilot study. J Pediatr Surg. 2013;48:1348-1356.
WardPE. Potential diagnostic aids for abnormal fatty acid metabolism in a range of neurodevelopmental disorders. Prostaglandins Leukot Essent Fatty Acids. 2000;63:65-68.
23.
DunstanJAMitoulasLRDixonG. The effects of fish oil supplementation in pregnancy on breast milk fatty acid composition over the course of lactation: a randomized controlled trial. Pediatr Res. 2007;62:689-694.
24.
HellandIBSmithLSaaremKSaugstadODDrevonCA. Maternal supplementation with very-long-chain n-3 fatty acids during pregnancy and lactation augments children’s IQ at 4 years of age. Pediatrics. 2003;111:e39-e44.
25.
BirchEEGarfieldSCastanedaYHughbanks-WheatonDUauyRHoffmanD. Visual acuity and cognitive outcomes at 4 years of age in a double-blind, randomized trial of long-chain polyunsaturated fatty acid-supplemented infant formula. Early Hum Dev. 2007;83:279-284.
26.
FewtrellMSAbbottRAKennedyK. Randomized, double-blind trial of long-chain polyunsaturated fatty acid supplementation with fish oil and borage oil in preterm infants. J Pediatr. 2004;144:471-479.
27.
FleithMClandininMT. Dietary PUFA for preterm and term infants: review of clinical studies. Crit Rev Food Sci Nutr. 2005;45:205-229.
SchonwaldAHuntingtonNChanERiskoWBridgemohanC. Routine developmental screening implemented in urban primary care settings: more evidence of feasibility and effectiveness. Pediatrics. 2009;123:660-668.
30.
SquiresJBrickerDPotterL. Revision of a parent-completed developmental screening tool: Ages and Stages Questionnaires. J Pediatr Psychol. 1997;22:313-328.
31.
Council on Children With Disabilities, Section on Developmental Behavioral Pediatrics, Bright Futures Steering Committee, Medical Home Initiatives for Children With Special Needs Project Advisory Committee. Identifying infants and young children with developmental disorders in the medical home: an algorithm for developmental surveillance and screening. Pediatrics. 2006;118:405-420.
32.
LimbosMMJoyceDP. Comparison of the ASQ and PEDS in screening for developmental delay in children presenting for primary care. J Dev Behav Pediatr. 2011;32:499-511.
33.
SicesLStancinTKirchnerLBauchnerH. PEDS and ASQ developmental screening tests may not identify the same children. Pediatrics. 2009;124:e640-e647.
34.
SchonhautLArmijoISchonstedtMAlvarezJCorderoM. Validity of the Ages and Stages Questionnaires in term and preterm infants. Pediatrics. 2013;131:E1468-E1474.
35.
ReynoldsCKamphausR. Behavior Assessment System for Children. 2nd ed.Circle Pines, MN: AGS Publishing; 2004.
36.
PapazoglouAJacobsonLAZabelT. Sensitivity of the BASC-2 Adaptive Skills Composite in detecting adaptive impairment in a clinically referred sample of children and adolescents. Clin Neuropsychologist. 2013;27:386-395.
37.
HollingsheadA. Four Factor Index of Social Status. New Haven, CT: Department of Sociology, Yale University; 1975.
38.
SquiresJTwombleyEBrickerD. Ages and Stages Questionnaire–3: A User’s Guide. Baltimore, MD: Brookes; 2009.
39.
GlascoeF. Collaborating With Parents: Using Parents’ Evaluations of Developmental Status to Detect and Address Developmental Problems in Children. Nashville, TN: Ellsworth and Vandermeer Press; 1988.
40.
GlascoeF. Parents’ Evaluations of Developmental Status: A Method for Detecting and Addressing Developmental and Behavioral Problems in Children. Nashville, TN: Ellsworth & Vandermeer Press; 1997.
41.
MeyersCBourJSidebottomKMurphyS. Same constructs, different results: examining the consistency of two behavior-rating scales with referred preschoolers. Psychol Schools. 2010;47:205-216.
42.
BraunJMKalkbrennerAECalafatAM. Impact of early-life Bisphenol A exposure on behavior and executive function in children. Pediatrics. 2011;128:873-882.
43.
RinaldiCMHoweN. Mothers’ and fathers’ parenting styles and associations with toddlers’ externalizing, internalizing, and adaptive behaviors. Early Child Res Q. 2012;27:266-273.
44.
Davis-BrunoKTassinariMS. Essential fatty acid supplementation of DHA and ARA and effects on neurodevelopment across animal species: a review of the literature. Birth Defects Res B Dev Reprod Toxicol. 2011;92:240-250.
45.
LammersEMJohnsonPNErnstKD. Association of fentanyl with neurodevelopmental outcomes in very-low-birth-weight infants. Ann Pharmacother. 2014;48(3):335-342.
46.
DurrmeyerXHummlerHSanchez-LunaM. Two-year outcomes of a randomized controlled trial of inhaled nitric oxide in premature infants. Pediatrics. 2013;132:e695-e703.
47.
ChawlaSBapatRPappasABaraRZidanMNatarajanG. Neurodevelopmental outcome of extremely premature infants exposed to incomplete, no or complete antenatal steroids. J Matern Fetal Neonatal Med. 2013;26:1542-1547.
48.
PayneAHHintzSRHibbsAM. Neurodevelopmental outcomes of extremely low-gestational-age neonates with low-grade periventricular-intraventricular hemorrhage. JAMA Pediatr. 2013;167:451-459.
49.
KonoYMishinaJYonemotoNKusudaSFujimuraM. Neonatal correlates of adverse outcomes in very low-birthweight infants in the NICU Network. Pediatrics Int. 2011;53:930-935.
50.
BarksJDLiuYQShangguanYLiJPfauJSilversteinFS. Impact of indolent inflammation on neonatal hypoxic-ischemic brain injury in mice. Int J Dev Neurosci. 2008;26:57-65.
51.
XiongTGonzalezFMuDZ. An overview of risk factors for poor neurodevelopmental outcome associated with prematurity. World J Pediatr. 2012;8:293-300.
52.
SereniusFKallenKBlennowM. Neurodevelopmental outcome in extremely preterm infants at 2.5 years after active perinatal care in Sweden. JAMA. 2013;309:1810-1820.
53.
OchiaiMKinjoTTakahataY. Survival and neurodevelopmental outcome of preterm infants born at 22-24 weeks of gestational age. Neonatology. 2013;105:79-84.
54.
FlickRPKatusicSKColliganRC. Cognitive and behavioral outcomes after early exposure to anesthesia and surgery. Pediatrics. 2011;128:e1053-e1061.
55.
WilderRTFlickRPSprungJ. Early exposure to anesthesia and learning disabilities in a population-based birth cohort. Anesthesiology. 2009;110:796-804.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
